GlassScriptPhysician profile
Eric S Hockstad
NPI 1053364265
$14,765.40
in general payments reported to CMS, 2019-2025
28 companies · $997 in 2025
The $997 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,030 · 2020: $368 · 2021: $213 · 2022: $839 · 2023: $1,239 · 2024: $2,078 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,314.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,456.47 | 2019-2025 | Xience Skypoint, Optis, Amplatzer Amulet |
| Medtronic, INC. | $1,355.97 | 2022-2025 | Resolute Onyx, Cobalt Dr Mri Surescan, Corevalve Evolut R |
| Boston Scientific Corporation | $1,308.47 | 2019-2025 | Watchman Access System, Watchman Flx, Avvigo Guidance System |
| Medtronic Vascular, INC. | $360.35 | 2019-2020 | |
| Amgen INC. | $277.84 | 2019-2025 | Repatha, Repatha |
| Biosense Webster, INC. | $271.12 | 2019-2024 | Qdot Micro Catheter |
| Philips North America LLC | $250.50 | 2020-2025 | (Ao0) Igt Devices Intracardiac, Eagle Eye |
| Abiomed | $225.38 | 2023-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $205.48 | 2019-2025 | Eliquis, Camzyos |
| Edwards Lifesciences Corporation | $161.12 | 2024 | |
| Cardiva Medical, INC. | $126.24 | 2024 | Cardiva Vascade 6/7f Vcs |
| Shockwave Medical, INC | $120.56 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $119.26 | 2019-2023 | Andexxa |
| Sanofi-Aventis U.S. LLC | $117.07 | 2019-2024 | |
| Novo Nordisk INC | $43.96 | 2024-2025 | Wegovy, Ozempic |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.88 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.19 | 2020-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $36.98 | 2022-2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $35.75 | 2024 | Arcalyst |
| W. L. Gore & Associates, INC. | $33.11 | 2019-2024 | Gore Cardioform Septal Occluder |
| Alnylam Pharmaceuticals INC. | $32.31 | 2019-2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $30.30 | 2019-2024 | Xarelto |
| Penumbra, INC. | $24.81 | 2025 | Penumbra System |
| Endotronix, INC. | $22.80 | 2024 | Cordella Pulomonary Artery Pressure Sensor |
| Regeneron Healthcare Solutions, INC. | $20.74 | 2025 | Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $16.02 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $15.74 | 2023 | Arcalyst |
| Chiesi USA, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Hockstad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.